Clinical Trial Update: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA [Phase 3]

View source ↗

Summary

Phase 3 trial in children evaluating dalbavancin for acute bacterial skin and skin structure infections caused by susceptible Gram-positive organisms including …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Skin and Skin Structure Infection
• Methicillin-resistant Staphylococcus Aureus Infection
• Staphylococcal Skin Infection

Drugs mentioned

• Dalvance (dalbavancin)

Snippet

Sponsor: AbbVie | Conditions: Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections | Phase 3 | Status: COMPLETED | Results posted: 2024-09-19